MAGEA4 and cancer: MAGE-A4 is widely expressed in many tumor types, including esophageal (60%), ovarian (47%), lung (19–35%), colorectal (22%), and breast (13%) cancers.[18,19] However, the involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of DTs remains unclear.